These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3498165)

  • 1. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
    McLaughlin J; Chianese E; Witte ON
    Proc Natl Acad Sci U S A; 1987 Sep; 84(18):6558-62. PubMed ID: 3498165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.
    Young JC; Witte ON
    Mol Cell Biol; 1988 Oct; 8(10):4079-87. PubMed ID: 3263566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
    McLaughlin J; Chianese E; Witte ON
    Mol Cell Biol; 1989 May; 9(5):1866-74. PubMed ID: 2747638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
    Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
    Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
    Ben-Neriah Y; Daley GQ; Mes-Masson AM; Witte ON; Baltimore D
    Science; 1986 Jul; 233(4760):212-4. PubMed ID: 3460176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients.
    Konopka JB; Clark S; McLaughlin J; Nitta M; Kato Y; Strife A; Clarkson B; Witte ON
    Proc Natl Acad Sci U S A; 1986 Jun; 83(11):4049-52. PubMed ID: 3012546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
    Lugo TG; Witte ON
    Mol Cell Biol; 1989 Mar; 9(3):1263-70. PubMed ID: 2725497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baculovirus expression of functional P210 BCR-ABL oncogene product.
    Pendergast AM; Clark R; Kawasaki ES; McCormick FP; Witte ON
    Oncogene; 1989 Jun; 4(6):759-66. PubMed ID: 2499863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonrandom cytogenetic changes accompany malignant progression in clonal lines abelson virus-infected lymphocytes.
    Clark SS; Liang Y; Reedstrom CK; Wu SQ
    Blood; 1994 Dec; 84(12):4301-9. PubMed ID: 7994046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity.
    Santucci MA; Anklesaria P; Laneuville P; Das IJ; Sakakeeny MA; FitzGerald TJ; Greenberger JS
    Int J Radiat Oncol Biol Phys; 1993 Aug; 26(5):831-6. PubMed ID: 8344852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
    Wertheim JA; Miller JP; Xu L; He Y; Pear WS
    Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines.
    Stacchini A; Ponzetto C; Guerrasio A; Martinotti G; Rege Cambrin G; Scaravaglio P; Rosso C; Piacibello W; Aglietta M; Saglio G
    Haematologica; 1989; 74(3):249-54. PubMed ID: 2511093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a translocated c-abl gene in hybrids of mouse fibroblasts and chronic myelogenous leukaemia cells.
    Kozbor D; Giallongo A; Sierzega ME; Konopka JB; Witte ON; Showe LC; Croce CM
    Nature; 1986 Jan 23-29; 319(6051):331-3. PubMed ID: 3455750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 5' non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells.
    Gishizky ML; McLaughlin J; Pendergast AM; Witte ON
    Oncogene; 1991 Aug; 6(8):1299-306. PubMed ID: 1886706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL induces multiple abnormalities of cytoskeletal function.
    Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
    J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.
    Kelliher M; Knott A; McLaughlin J; Witte ON; Rosenberg N
    Mol Cell Biol; 1991 Sep; 11(9):4710-6. PubMed ID: 1875948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.